Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, August 21, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, August 18, 2023
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Maintained (CALT) at Hold with Decreased Target to $18 on, Aug 18th, 2023
Vamil Divan of Guggenheim, Maintained "Calliditas Therapeutics AB (publ)" (CALT) at Hold with Decreased Target from $21 to $18 on, Aug 18th, 2023.
Vamil has made no other calls on CALT in the last 4 months.
There is 1 other peer that has a rating on CALT. Out of the 1 peers that are also analyzing CALT, 0 agree with Vamil's Rating of Hold.
This is the rating of the analyst that currently disagrees with Vamil
- Edwin Zhang of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $60 on, Tuesday, June 20th, 2023
